Current Issues of Pharmacy and Medical Sciences

An analysis of potential costs of adverse events based on Drug Programs in Poland. Pulmonology focus

Curr Issues Pharm Med Sci., Vol. 27, No. 1, Pages 32-36

Monika Szkultecka-Dębek1, Mariola Drozd2, Karina Jahnz-Różyk3, Nina Kiepurska 1, Joanna Mazurek3,
Agnieszka Janowska4, Piotr Paprzycki4, Marta Adamczyk-Korbel5, Beata Paluchowska1, Kazimierz Drozd6

1 Department of Dermatology, Military Institute of Medicine, Warsaw, Poland

2 Department of Applied Pharmacy, Medical University of Lublin, Poland

3 Department of Immunology and Clinical Allergology, Military Institute of Medicine, Warsaw, Poland

4 Department of Functional Research, Institute of Rural Health in Lublin

5 Chair and Department of Pneumology, Oncology and Allergology, Medical University of Lublin, Poland

6 Department of Materials Engineering, Lublin University of Technology, Poland


DOI: 10.2478/cipms-2014-0009

Abstract

The project was performed within the Polish Society for Pharmacoeconomics (PTFE). The objective was to estimate the potential costs of treatment of side effects, which theoretically may occur as a result of treatment of selected diseases . We analyzed the Drug Programs financed by National Health Fund in Poland in 2012 and for the first analysis we selected  those Programs where the same medicinal products were used. We based the adverse events selection on the Summary of Product Characteristics of the chosen products. We extracted all the potential adverse events defined as frequent and very frequent, grouping them according to therapeutic areas. This paper is related to the results in the pulmonology area. The events described as very common had an incidence of ≥ 1/10, and the common ones ≥ 1/100, <1 /10. In order to identify the resources used, we performed a survey with the engagement of clinical experts. On the basis of the collected data we allocated direct costs incurred by the public payer. We used the costs valid in December 2013. The paper presents the estimated costs of treatment of side effects related to the pulmonology disease area. Taking into account the costs incurred by the NHF and the patient separately we calculated the total spending and the percentage of each component cost in detail. The treatment of adverse drug reactions generates a significant cost incurred by both the public payer and the patient.

 

Full Text

Keywords

health care costs, adverse drug events, pulmonary medicine

References

  1. Agencja Oceny Technologii Medycznych: Wytyczne oceny tech­nologii medycznych (HTA) wersja 2.1. Warszawa, kwiecień 2009. Online: http://www.aotm.gov.pl/assets/files/wytyczne_hta/2009/Wytyczne_HTA_pl_MS_29052009.pdf, access: 2014.01.19
  2. Allué N., Chiarello P., Bernal Delgado E., Castells X., Giraldo P., Martínez N., Sarsanedas E., Cots F.: Impacto económico de los eventos adversos en los hospitales españoles a partir del Conjunto Mínimo Básico de Datos” Assessing the economic impact of adverse events in Spanish hospitals by using administrative data. Gaceta Sanitaria, 2014, 1-2, s. 48-54.
  3. Gautier S., Bachelet H., Bordet R., Caron J.: The cost of adverse drug reactions. Expert Opin. Pharmacother. 2003, 4, 3, s. 319-326.
  4. Pattanaik S., Dhamija P., Malhotra S., Sharma N., Pandhi P.: Eva­luation of cost of treatment of drug-related events in a tertiary care public sector hospital in Northen India: a prospective study. British Journal of Clinical Pharmacology. 2009, 67, 3, s. 363-369.
  5. Pliki parametryzujące. online: http://jgp.uhc.com.pl/doc/index.html, Access: 2014.01.06.
  6. Rozporządzenie Ministra Zdrowia z 2 kwietnia 2012 roku w sprawie minimalnych wymagań jakie muszą spełniać analizy uwzględnione we wnioskach o objęcie refundacją i ustalenie urzędowej ceny zbytu oraz podwyższenie urzędowej ceny zbytu leku, środka spożywczego specjalnego przeznaczenia, wyrobu medycznego, które nie mają odpowiednika refundowanego w danym wskazaniu. Dz. U. 2012, poz. 388.
  7. Szkultecka-Debek M., Drozd M., Wiśniewska N., Drozd K.: Adverse events (AE) cost assessed in Poland based on existing Drug programs – methodology of the project. Curr. Issues Pharm. Med. Sci. 2013, 26, 4, p. 422-424.
  8. Ustawa z dn. 12 maja 2011 roku o refundacji leków, środków spo­żywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych. Dz. U. 2011 nr 122 poz. 696 z późn. zm.
  9. Wiśniewska N., Szkultecka-Dębek M., Owczarek W., Paluchowska E., Jahnz-Różyk K.: The direct costs of drug-induced skin reactions in Poland. Value in Health, 16, 7, 2013, s. A696.
  10. Załącznik do Obwieszczenia Ministra Zdrowia z dnia 25 paździer­nika 2013 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na dzień 1 listopada 2013 r. http://www2.mz.gov.pl/wwwmz/index?mr=q491&ms=383&ml=pl&mi=383&mx=0&m­t=&my=419&ma=32785, access: 2013.11.04.

Calendar

April 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30